Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Ophthalmic Physiol Opt ; 41(2): 255-265, 2021 03.
Artigo em Inglês | MEDLINE | ID: mdl-33427324

RESUMO

PURPOSE: People with age-related macular degeneration (AMD) experience high rates of depression, but rarely engage in or have access to tailored mental wellbeing programmes. This qualitative study investigated the perspectives of those primarily with late AMD on mental health and mental wellbeing programmes. METHODS: Twenty-eight people with late AMD in at least one eye, and one person with early AMD in both eyes, aged 56-87 years (mean age 78 years) attending a private eye clinic between December 2019 and January 2020 in Sydney, New South Wales, Australia, participated. Individual semi-structured interviews were conducted and analysed deductively using content analysis, following the individual level factors for health promotion interventions in the behaviour change wheel: Capability (Physical & Psychological), Opportunity (Physical & Social), and Motivation (Reflective & Automatic). RESULTS: Six major themes were identified: Capability: (1) Impact of vision loss on mobility and leisure pursuits; (2) Adjustment to living with vision loss; Opportunity: (3) Program considerations for those with AMD; (4) Stigma and self-perception of vision loss and mental health; Motivation: (5) Accumulation of vision-related issues as a barrier to participation; (6) Examples of others living with vision loss. General personal factors relevant to delivery of a programme in this age group were also identified: Comorbidities; Limitations using technology; Isolation; Financial concerns and Beliefs that undesired effects of aging are inevitable. CONCLUSIONS: Complex individual, environmental and social factors influence the perspectives of people with late AMD on mental health, and potential participation in mental wellbeing programmes. These factors should be considered when developing and implementing mental wellbeing programmes to improve the emotional and functional rehabilitation outcomes for people with AMD.


Assuntos
Depressão/epidemiologia , Degeneração Macular/reabilitação , Cura Mental/psicologia , Saúde Mental , Avaliação de Programas e Projetos de Saúde/métodos , Pesquisa Qualitativa , Acuidade Visual , Idoso , Idoso de 80 Anos ou mais , Depressão/etiologia , Depressão/reabilitação , Feminino , Seguimentos , Humanos , Degeneração Macular/complicações , Degeneração Macular/psicologia , Masculino , Pessoa de Meia-Idade , Morbidade/tendências , New South Wales/epidemiologia , Estudos Retrospectivos , Autoimagem , Fatores de Tempo
2.
Lancet ; 392(10153): 1147-1159, 2018 09 29.
Artigo em Inglês | MEDLINE | ID: mdl-30303083

RESUMO

Age-related macular degeneration is a leading cause of visual impairment and severe vision loss. Clinically, it is classified as early-stage (medium-sized drusen and retinal pigmentary changes) to late-stage (neovascular and atrophic). Age-related macular degeneration is a multifactorial disorder, with dysregulation in the complement, lipid, angiogenic, inflammatory, and extracellular matrix pathways implicated in its pathogenesis. More than 50 genetic susceptibility loci have been identified, of which the most important are in the CFH and ARMS2 genes. The major non-genetic risk factors are smoking and low dietary intake of antioxidants (zinc and carotenoids). Progression from early-stage to late-stage disease can be slowed with high-dose zinc and antioxidant vitamin supplements. Intravitreal anti-vascular endothelial growth factor therapy (eg, ranibizumab, aflibercept, or bevacizumab) is highly effective at treating neovascular age-related macular degeneration, and has markedly decreased the prevalence of visual impairment in populations worldwide. Currently, no proven therapies for atrophic disease are available, but several agents are being investigated in clinical trials. Future progress is likely to be from improved efforts in prevention and risk-factor modification, personalised medicine targeting specific pathways, newer anti-vascular endothelial growth factor agents or other agents, and regenerative therapies.


Assuntos
Degeneração Macular , Progressão da Doença , Humanos , Incidência , Degeneração Macular/classificação , Degeneração Macular/diagnóstico , Degeneração Macular/tratamento farmacológico , Degeneração Macular/epidemiologia , Prevalência , Fatores de Risco , Fator A de Crescimento do Endotélio Vascular/antagonistas & inibidores
3.
Nutrients ; 9(2)2017 Feb 09.
Artigo em Inglês | MEDLINE | ID: mdl-28208784

RESUMO

Lutein and zeaxanthin (L/Z) are the predominant carotenoids which accumulate in the retina of  the eye. The impact of L/Z intake on the risk and progression of age-related macular degeneration (AMD),  a leading cause of blindness in the developed world, has been investigated in cohort studies and clinical  trials. The aims of this review were to critically examine the literature and evaluate the current evidence  relating to L/Z intake and AMD, and describe important food sources and factors that increase the  bioavailability of L/Z, to inform dietary models. Cohort studies generally assessed L/Z from dietary  sources, while clinical trials focused on providing L/Z as a supplement. Important considerations to take  into account in relation to dietary L/Z include: nutrient-rich sources of L/Z, cooking methods, diet variety  and the use of healthy fats. Dietary models include examples of how suggested effective levels of L/Z can  be achieved through diet alone, with values of 5 mg and 10 mg per day described. These diet models  depict a variety of food sources, not only from dark green leafy vegetables, but also include pistachio nuts  and other highly bioavailable sources of L/Z such as eggs. This review and the diet models outlined  provide information about the importance of diet variety among people at high risk of AMD or with early  signs and symptoms of AMD.


Assuntos
Dieta/métodos , Suplementos Nutricionais , Análise de Alimentos , Luteína/análise , Degeneração Macular/prevenção & controle , Zeaxantinas/análise , Disponibilidade Biológica , Humanos , Luteína/farmacocinética , Zeaxantinas/farmacocinética
4.
PLoS One ; 10(3): e0122548, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25822372

RESUMO

We aimed to compare the micronutrient usage and other lifestyle behaviors over 10 years among those with and without age-related macular degeneration (AMD). 1612 participants aged 49+ years at baseline were re-examined over 10 years, west of Sydney, Australia. AMD was assessed from retinal photographs. Dietary data were collected using a semi-quantitative food frequency questionnaire. Smoking status was self-reported. 56 participants had any AMD at baseline, of these 25% quit smoking at 5 years and were still not smoking at 10-year follow-up. Among participants who had below the recommended intake of vitamins A, C or E supplements at baseline, those who did compared to those who did not develop late AMD over 10 years were more likely to report vitamins A (total), C or E supplement intake above the recommended intake at 10-year follow-up: multivariable-adjusted OR 4.21 (95% CI 1.65-10.73); OR 6.52 (95% CI 2.76-15.41); and OR 5.71 (95% CI 2.42-13.51), respectively. Participants with compared to without AMD did not appreciably increase fish, fruit and vegetable consumption and overall diet quality. Adherence to smoking and dietary recommendations was poor among older adults with AMD. However, uptake of antioxidant supplements increased significantly among those with late AMD.


Assuntos
Antioxidantes/farmacologia , Dieta , Suplementos Nutricionais , Degeneração Macular/epidemiologia , Fumar/efeitos adversos , Idade de Início , Idoso , Feminino , Humanos , Estilo de Vida , Masculino , Pessoa de Meia-Idade , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA